Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Betting On A Brexit Transition Period Is A Gamble: EMA Warning For Industry

Executive Summary

A senior official at the European Medicines Agency has warned pharmaceutical companies are taking a risk by endlessly waiting to get news on whether there would be a Brexit transition period. Drug makers still waiting to prepare for changes that may be needed once the UK leaves the EU were told 'this is your risk and your decision.'

You may also be interested in...

EMA Explains How To Make Brexit-Related MA Changes, As Industry Bodies Urge Transition Period

The EMA has produced further guidance for pharmaceutical companies on the changes they will need to make as a result of Brexit, focusing on activities such as transfers of marketing authorizations and orphan designations, and changes to personnel responsible for pharmacovigilance and batch recalls. Meanwhile, UK and European industry bodies say there is not enough time to make the necessary changes and that a transition period is needed.

Brexit: How Do Pharma Firms Plan For An Unknown Scenario?

As the Brexit negotiations continue, the pharmaceutical industry is anxious to have a cut-off date when it should start taking action to deal with the legal repercussions of the UK becoming a third country within the context of the EU medicines network. There are no clear answers yet, and companies are being asked to continue to wait and watch.

Change And More Change: That’s What Brexit Means For Drug Companies

The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts